Identified 56 therapeutic activities of GSNO and GSNORis, including SPL-850 in ocular, autoimmune, neurodegenerative,
cardiovascular, respiratory, and metabolic disease.
Filed wide international patent rights for SPL-850 and related
molecules, claiming composition of matter in autoimmune, ocular, cardiovascular, and fibrotic diseases.
Clean safety data for SPL-850. Novel PK/PD for SPL-850 and active routes of administration: oral, topical, intravitreal, IP, IV.